Zai Lab Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Zai Lab wird ein jährliches Gewinn- und Umsatzwachstum von 34.4% bzw. 23.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -37.3% betragen.
Wichtige Informationen
34.4%
Wachstumsrate der Gewinne
26.40%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 27.6% |
| Wachstumsrate der Einnahmen | 23.3% |
| Zukünftige Eigenkapitalrendite | -37.31% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 10 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • 2h
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates
Zai Lab Limited ( NASDAQ:ZLAB ) just released its quarterly report and things are looking bullish. Results overall were...Analyseartikel • May 11
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Zai Lab Limited ( NASDAQ:ZLAB ), who've watched their investment drop 12% to US$18.60 in the...Analyseartikel • Nov 09
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Zai Lab Limited ( NASDAQ:ZLAB ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...Recent updates
Analyseartikel • 2h
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates
Zai Lab Limited ( NASDAQ:ZLAB ) just released its quarterly report and things are looking bullish. Results overall were...
Narrative-Update • Aug 07
ZLAB: Global Pipeline Progress And Regulatory Milestones Will Shape A Measured Re Rating
Zai Lab’s updated analyst price target has moved from $21.80 to $24.25. Analysts cite the company’s shift from a China-focused commercial story to a broader global innovation profile as a key driver in their revised view.
Narrative-Update • Jun 18
ZLAB: DLL3 Program And China Approval Will Drive Long-Term Upside
The analyst price target for Zai Lab has been adjusted slightly lower to $33.30 from $33.78, with analysts citing incremental updates to fair value estimates, the discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Zai Lab Zai Lab received approval from China’s National Medical Products Administration for TIVDAK to treat adult patients with recurrent or metastatic cervical cancer whose disease progressed after chemotherapy, supported by overall survival data from the Phase 3 innovaTV 301 trial (primary news, NMPA filing).Analyseartikel • Jun 16
Zai Lab (ZLAB) Stock Could Be 47.5% Undervalued After China Approved TIVDAK
Zai Lab (ZLAB) stock is in focus after China’s National Medical Products Administration approved TIVDAK for adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. See our latest analysis for Zai Lab. The NMPA approval for TIVDAK comes after a mixed stretch for Zai Lab, with the stock showing a 1-day share price return of 3.87% and a 7-day share price return of 7.58%, yet a 1-year total shareholder return that declined 56.36%. This suggests...Narrative-Update • Jun 03
ZLAB: DLL3 Combinations And Fast Track Designation Will Support Long-Term Expansion
Analysts have reduced their price target on Zai Lab by $7, reflecting updated views on fair value, discount rates, growth assumptions, margins, and future P/E expectations following recent research. What's in the News President and COO Josh Smiley plans to leave Zai Lab effective May 22, 2026, as part of a broader leadership reshuffle related to operational efficiency efforts and preparations for the launch of COBENFY in China and several oncology data readouts in 2026, according to recent company announcements.Seeking Alpha • May 13
Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached
Summary Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues, shifting focus to global pipeline assets. I assign zero intrinsic value to ZLAB's China business, given minimal "bottom line" contributions from blockbuster launches like Vyvgart and anticipated similar outcomes for KarXT. Zoci, a wholly owned Phase 3 oncology asset, is the key value driver for the company, with a modeled global rNPV near $1 billion and potential for multi-billion upside if expanded to 1L SCLC. I maintain a Speculative Buy rating on ZLAB, as its valuation hinges almost entirely on Zoci's clinical and commercial success, with risks from cash burn and competition. Read the full article on Seeking AlphaAnalyseartikel • May 11
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Zai Lab Limited ( NASDAQ:ZLAB ), who've watched their investment drop 12% to US$18.60 in the...Narrative-Update • May 01
ZLAB: Diversified Pipeline And DLL3 Partnerships Will Support Long-Term Expansion
The analyst price target for Zai Lab has been reduced by about $14 to $35, with analysts citing lower modeled revenue growth, modestly higher discount rates, and management's commentary on more modest 2026 top line expectations given pricing pressures and competition in China. Analyst Commentary Recent Street research on Zai Lab points to a more cautious stance on revenue growth and valuation, with several firms trimming their price targets while still recognizing areas of execution strength and pipeline potential.Narrative-Update • Apr 16
ZLAB: Cautious China Outlook And Pipeline Progress Will Shape A Measured Re Rating
Analysts have lowered their average price targets on Zai Lab by several dollars, citing more cautious expectations for 2026 revenue growth. Management anticipates modest top line trends with pricing pressure and rising competition in China, which is reflected in slightly adjusted P/E assumptions and growth inputs.Narrative-Update • Apr 02
ZLAB: Mixed Coverage And Pipeline Progress Will Shape A Measured Re Rating
Analysts have trimmed their price targets on Zai Lab, and the model update now points to a fair value of $21.80. This reflects expectations for more modest revenue growth and profit margins, along with a higher future P/E multiple.
Narrative-Update • Mar 19
ZLAB: China Approvals And Oncology Pipeline Progress Will Support Future Upside Potential
Analysts have trimmed their price targets on Zai Lab by up to $18, reflecting more cautious assumptions on revenue growth and competitive pressures. At the same time, updated models incorporate a higher projected profit margin and a lower future P/E multiple.Narrative-Update • Mar 04
ZLAB: China Approvals And Pipeline Execution Will Support Future Upside Potential
Narrative Update The updated analyst price target for Zai Lab has moved down from $67.22 to $55.00 as analysts factor in more modest projected revenue growth, lower profit margins, a higher assumed discount rate, and recent Street research pointing to pricing pressure, competition in China, and adjustments to company models following management commentary. Analyst Commentary Recent Street research on Zai Lab shows a mix of recalibrated price targets and ongoing constructive views on execution and longer term growth prospects.Narrative-Update • Feb 17
ZLAB: Mixed Coverage And New Approvals Will Shape A Measured Re Rating
Analysts trimmed their price targets on Zai Lab by $3.03, reflecting updated fair value and P/E assumptions, as well as fresh views on the company following recent research coverage changes. Analyst Commentary Recent Street research on Zai Lab has sent a mixed message, with some optimism around longer term potential but also fresh caution on how the current share price lines up with execution risks and valuation assumptions.Narrative-Update • Feb 03
ZLAB: Fresh Coverage And Pipeline Progress Will Support A Re Rating
The updated analyst price target for Zai Lab moves to about US$23.45 from about US$28.14, as analysts factor in lower revenue growth assumptions and a lower future P/E multiple, partly offset by higher projected profit margins and supported by fresh coverage and a US$35 target from recent Street research. Analyst Commentary While the updated blended price target for Zai Lab sits around US$23.45, investor sentiment is being pulled in different directions.Narrative-Update • Jan 20
ZLAB: Pipeline And New China Approvals Will Drive Future Upside Potential
Analysts have nudged their fair value estimate for Zai Lab to US$67.22 per share, reflecting slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E following fresh coverage initiation and list changes in recent Street research. Analyst Commentary Street research on Zai Lab has been mixed recently, but the latest fair value update and fresh coverage suggest that some bullish analysts still see room for upside relative to current pricing.Narrative-Update • Jan 06
ZLAB: Pipeline Execution After Conviction List Removal Will Drive Upside Potential
Analysts have trimmed their fair value estimate for Zai Lab from US$74.00 to US$67.22, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples following its removal from a regional conviction list by a major broker. Analyst Commentary Goldman Sachs removed Zai Lab from its APAC Conviction List as part of a broader monthly review, which has prompted some investors to reassess expectations and risk appetite around the stock.Narrative-Update • Dec 20
ZLAB Removed From Conviction List Yet Future Pipeline Progress May Re-Rate Shares
Analysts have cut their price target on Zai Lab from approximately $39 to about $28, reflecting a materially lower growth outlook and higher perceived risk, as evidenced by its recent removal from a major APAC conviction list. Analyst Commentary Bearish analysts have interpreted the removal of Zai Lab from a major APAC conviction list as a signal that the company may face a more challenging path to justifying a premium valuation, particularly given rising competition and execution uncertainties in its pipeline and commercialization strategy.Narrative-Update • Dec 06
ZLAB: Diversified Pipeline Is Expected To Drive Long-Term Market Expansion
Narrative Update on Zai Lab Analysts have moderately lowered their price target on Zai Lab to approximately $49.49, reflecting more conservative assumptions for revenue growth and profit margins, along with the stock’s recent removal from a key regional conviction list. Analyst Commentary Recent research updates on Zai Lab have prompted a more nuanced view of the company’s risk and reward profile, with analysts highlighting both supportive fundamentals and execution challenges that could influence the stock’s re-rating trajectory.Narrative-Update • Nov 22
ZLAB: Pipeline Diversification And Ongoing Partnerships Will Support Long-Term Market Expansion
Zai Lab's analyst price target has been revised downward from approximately $53.40 to $49.49. Analysts cite concerns over slowing revenue growth and narrowing profit margins.Analyseartikel • Nov 09
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Zai Lab Limited ( NASDAQ:ZLAB ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...Analyseartikel • Nov 07
Analyst Forecasts Just Became More Bearish On Zai Lab Limited (NASDAQ:ZLAB)
Market forces rained on the parade of Zai Lab Limited ( NASDAQ:ZLAB ) shareholders today, when the analysts downgraded...Narrative-Update • Nov 07
ZLAB: Future Product Launches Will Drive Broader Market Reach And Patient Access
Analysts have lowered their price target for Zai Lab from approximately $55.41 to $53.40. They cite adjustments in key financial projections and the company's recent removal from a major conviction list as supporting factors.Analyseartikel • Nov 06
Revenues Working Against Zai Lab Limited's (NASDAQ:ZLAB) Share Price Following 26% Dive
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders that were waiting for something to happen have been dealt a blow with a...Analyseartikel • Oct 05
Is Zai Lab (NASDAQ:ZLAB) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrative-Update • Sep 23
Expanding China Healthcare And Global Pipelines Will Broaden Patient Options
Despite encouraging Phase III trial data for bemarituzumab in gastric cancer, which bolsters near-term commercial outlooks and regulatory momentum in China, Zai Lab’s consensus analyst price target saw only a slight downward adjustment from $56.31 to $55.41. Analyst Commentary Positive Phase III FORTITUDE-101 trial data for bemarituzumab in first-line FGFR2b+ gastric cancer.Analyseartikel • Jun 16
Revenues Not Telling The Story For Zai Lab Limited (NASDAQ:ZLAB) After Shares Rise 33%
Zai Lab Limited ( NASDAQ:ZLAB ) shares have had a really impressive month, gaining 33% after a shaky period beforehand...
Neues Narrative • Apr 30
New VYVGART And Pipeline Advances Will Expand Global Markets
Strong revenue growth is expected due to robust product launches and pipeline innovations, with profitability anticipated through cost optimization and operational efficiencies.Seeking Alpha • Mar 20
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
Summary ZLAB’s Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB’s main growth drivers. ZLAB’s ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China. ZLAB’s balance sheet is pretty solid, with close to 2.4 years of runway, and aiming towards profitability by yearend 2025. ZLAB’s valuation is higher than when I first covered it. New trade risks between the US and China also exist, but I remain bullish at these levels. Read the full article on Seeking AlphaAnalyseartikel • Mar 06
Zai Lab Limited's (NASDAQ:ZLAB) 31% Share Price Surge Not Quite Adding Up
Zai Lab Limited ( NASDAQ:ZLAB ) shareholders have had their patience rewarded with a 31% share price jump in the last...Analyseartikel • Jan 20
Investors Don't See Light At End Of Zai Lab Limited's (NASDAQ:ZLAB) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Zai Lab Limited ( NASDAQ:ZLAB ) is a stock worth...Seeking Alpha • Dec 26
Zai Lab: Rapidly Improving Outlook Bodes Well For The Future
Summary Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the Chinese market, with key products like Zejula, Qinlock, Nuzyra, Vyvgart, and Optune driving revenue. Despite high costs, ZLAB's consistent quarterly revenue growth and a strong cash position indicate a promising future. Zai Lab's unique market position and strong pipeline make it a compelling investment for those with high risk tolerance. Read the full article on Seeking AlphaAnalyseartikel • Nov 15
The Zai Lab Limited (NASDAQ:ZLAB) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
There's been a notable change in appetite for Zai Lab Limited ( NASDAQ:ZLAB ) shares in the week since its...Analyseartikel • Sep 28
Zai Lab Limited (NASDAQ:ZLAB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Zai Lab Limited ( NASDAQ:ZLAB ) shares have continued their recent momentum with a 26% gain in the last month alone...Analyseartikel • Sep 23
Zai Lab (NASDAQ:ZLAB) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 12
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Key Insights Zai Lab will host its Annual General Meeting on 18th of June Salary of US$868.5k is part of CEO Samantha...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 721 | -152 | -58 | -25 | 11 |
| 12/31/2027 | 573 | -178 | -148 | -93 | 16 |
| 12/31/2026 | 423 | -244 | -208 | -153 | 10 |
| 6/30/2026 | 450 | -188 | -163 | -133 | N/A |
| 3/31/2026 | 453 | -178 | -133 | -101 | N/A |
| 12/31/2025 | 460 | -176 | -164 | -151 | N/A |
| 9/30/2025 | 442 | -207 | -210 | -181 | N/A |
| 6/30/2025 | 428 | -213 | -231 | -175 | N/A |
| 3/31/2025 | 418 | -252 | -239 | -186 | N/A |
| 12/31/2024 | 399 | -257 | -276 | -215 | N/A |
| 9/30/2024 | 356 | -271 | -219 | -174 | N/A |
| 6/30/2024 | 323 | -298 | -215 | -202 | N/A |
| 3/31/2024 | 291 | -339 | -223 | -219 | N/A |
| 12/31/2023 | 267 | -335 | -193 | -198 | N/A |
| 9/30/2023 | 263 | -301 | -291 | -293 | N/A |
| 6/30/2023 | 252 | -393 | -371 | -364 | N/A |
| 3/31/2023 | 231 | -410 | -368 | -350 | N/A |
| 12/31/2022 | 215 | -443 | -393 | -368 | N/A |
| 9/30/2022 | 197 | -593 | -438 | -411 | N/A |
| 6/30/2022 | 182 | -529 | -472 | -446 | N/A |
| 3/31/2022 | 171 | -554 | -494 | -467 | N/A |
| 12/31/2021 | 144 | -704 | -568 | -549 | N/A |
| 9/30/2021 | 115 | -569 | -458 | -441 | N/A |
| 6/30/2021 | 87 | -537 | -374 | -359 | N/A |
| 3/31/2021 | 61 | -454 | -357 | -346 | N/A |
| 12/31/2020 | 49 | -269 | -227 | -216 | N/A |
| 9/30/2020 | 39 | -239 | -219 | -212 | N/A |
| 6/30/2020 | 29 | -240 | -212 | -200 | N/A |
| 3/31/2020 | 19 | -201 | N/A | -189 | N/A |
| 12/31/2019 | 13 | -195 | N/A | -191 | N/A |
| 9/30/2019 | 8 | -212 | N/A | -196 | N/A |
| 6/30/2019 | 4 | -181 | N/A | N/A | N/A |
| 3/31/2019 | 2 | -160 | N/A | N/A | N/A |
| 12/31/2018 | 0 | -139 | N/A | -98 | N/A |
| 9/30/2018 | N/A | -89 | N/A | N/A | N/A |
| 6/30/2018 | N/A | -67 | N/A | N/A | N/A |
| 3/31/2018 | N/A | -59 | N/A | N/A | N/A |
| 12/31/2017 | N/A | -50 | N/A | -32 | N/A |
| 9/30/2017 | N/A | -50 | N/A | N/A | N/A |
| 6/30/2017 | N/A | -50 | N/A | -41 | N/A |
| 3/31/2017 | N/A | -44 | N/A | -37 | N/A |
| 12/31/2016 | N/A | -38 | N/A | -32 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ZLAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ZLAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ZLAB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ZLABDie Einnahmen des Unternehmens (23.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.9% pro Jahr).
Hohe Wachstumseinnahmen: ZLABDie Einnahmen des Unternehmens (23.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ZLAB wird voraussichtlich in 3 Jahren unrentabel sein.
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/10 08:06 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Zai Lab Limited wird von 34 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rebecca Liang | Bernstein |
| Bo Li | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |